Product Preview ModernMedicine The FDA has accepted for review Astellas Pharma US, Inc.'s new drug application (NDA) for tacrolimus (Prograf) extended-release capsules, for the prophylaxis of organ rejection in adult kidney transplant recipients and adult male liver transplant ... |
